FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Executive Summary
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
You may also be interested in...
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
US agency's Office of Prescription Drug Promotion may complete 37% fewer drug promotional material reviews in FY 2017 than previous year.
Woodcock Wants Rapid Regulatory Policy Development
CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.
Woodcock Wants Rapid Regulatory Policy Development
CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.